Company: PCRX
Filing Date: 2025-04-17
Form Type: DEFA14A
Source: 0001104659-25-036098
Chunk: 0

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-17
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934</div>

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

| ¨ | Preliminary Proxy Statement                                                     |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ | Definitive Proxy Statement                                                      |
| ¨ | Definitive Additional Materials                                                 |
| x | Soliciting Material under §240.14a-12                                           |

<div align='center'>PACIRA BIOSCIENCES, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| x | No fee required.                                                                                    |
| ¨ | Fee paid previously with preliminary materials.                                                     |
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

On April 17, 2025, Pacira BioSciences, Inc. issued the following press release:

FOR IMMEDIATE RELEASE

NEWS RELEASE

<div align='center'>Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

-- $300 million aggregate share repurchase authorization--

-- Reinforces confidence in 5x30 plan –

-- Continued focus on margin expansion and operational efficiency --</div>

BRISBANE, CA, April 17, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid
pain therapies to transform the lives of patients, today reaffirmed its commitment to enhancing shareholder value by outlining a series
of strategic actions designed to optimize operational performance and create sustainable, long-term value for shareholders.

The company has made meaningful progress advancing its 5x30
strategy to transition into an innovative biopharmaceutical organization and become a therapeutic area leader in musculoskeletal pain
and adjacencies. The Board and management team see a clear path to achieving the following key objectives by 203